RedHill Biopharma Announces Positive Top-line Results from YELIVA(TM) (ABC294640) Phase I Study in Advanced Solid Tumors
— The Phase I study with YELIVA(TM) (ABC294640) successfully met its primary and secondary endpoints, demonstrating that the drug is well tolerated and can be safely administered to cancer patients at doses that provide circulating drug levels that are predicted to have therapeutic Activity — Twenty-one patients with advanced solid tumors were treated with YELIVA(TM) […]